Millions lose access to free NHS earwax removal
Patients unable to afford private treatment are turning to “dangerous self-removal methods”, the RNID says.
Similar Posts
Cambridge lab grows 'mini-placentas' for pre-eclampsia study
Pre-eclampsia affects millions of women worldwide yet is little understood, say scientists.
These 8 health screenings should be on your calendar for 2024, according to doctors
Read this article for free! Plus get unlimited access to thousands of articles, videos and more with your free account! Please enter a valid email address. By entering your email, you are agreeing to Fox News Terms of Service and Privacy Policy, which includes our Notice of Financial Incentive. To access the content, check your…
Alzheimer’s patients divided into 5 subgroups, potentially enabling ‘personalized medicine,’ study finds
Read this article for free! Plus get unlimited access to thousands of articles, videos and more with your free account! Please enter a valid email address. By entering your email, you are agreeing to Fox News Terms of Service and Privacy Policy, which includes our Notice of Financial Incentive. To access the content, check your…
Medics told not to report illegal abortions to police
Abortions are legal in England if they are performed by a registered medical practitioner and take place within the first 24 weeks of pregnancy. Otherwise, it is illegal to deliberately end a pregnancy and, under the 1861 Offences Against the Person Act, it carries a maximum punishment of life imprisonment.
Ask a health expert: ‘Should I take Paxlovid if I have COVID?’
Join Fox News for access to this content Plus get unlimited access to thousands of articles, videos and more with your free account! Please enter a valid email address. By entering your email, you are agreeing to Fox News Terms of Service and Privacy Policy, which includes our Notice of Financial Incentive. To access the…
Moderna stock jumps after Oppenheimer upgrade on pipeline potential
Artur Widak | Nurphoto | Getty Images Shares of Moderna closed more than 13% higher on Tuesday after Oppenheimer upgraded the stock to “outperform,” saying the Covid vaccine maker could market five products by 2026. The upgrade follows a dismal 2023 for Moderna, whose only commercially available product is its Covid shot. The company’s stock…